With the recent FDA approvals of Venetoclax and Glasdegib in AML, is one generally preferred over the other for elderly and/or unfit patients in combination with a hypomethylating agent/low-dose cytarabine?

Overall the combination of venetoclax with HMA or LDAC for newly diagnosed older AML patients is generally preferred for treatment of this subset of AML patients due to reports of high overall response rates (60-70%) and prolonged overall survival (median 18 months). Prior studies have shown that gl...